Published • loading... • Updated
NHS ‘worst in Europe’ for paying for drugs, says Mounjaro maker
Eli Lilly's CEO warns UK pricing and rebate policies deter investment and new medicines, with nearly 23% NHS rebate cited as a key challenge, risking patient access to treatments.
- Dave Ricks, chief executive of Eli Lilly and Company, told the Financial Times the UK is the least attractive market in Europe and warned companies may withhold new medicines and investment unless pricing rules change.
- Amid rising rebate levels, Ricks highlighted the VPAG clawback, which he described as punishing success and should be removed.
- Industry figures show drug companies have suspended or cancelled almost 1.8 billion of UK investment this year, with four major projects worth over 1.8 billion abandoned.
- Lilly sharply raised Mounjaro's private price by up to 170 per cent last month amid cross-border buying, and Ricks warned UK patients could miss treatments while legal action looms.
- The UK government earlier this month said more work is needed to change the life sciences landscape, with investments of up to 600m and 520m supporting an estimated 100bn sector and over 300,000 jobs.
Insights by Ground AI
7 Articles
7 Articles
UK 'worst country in Europe' for drug prices - and it could cost patients new medicines, warns Mounjaro maker
Britain has come under fire from one of the world’s biggest drug companies, which says the UK is the least attractive market in Europe for medicine makers
·London, United Kingdom
Read Full ArticleDollar makes gains, UK slammed by pharmaceutical CEO
The dollar grew throughout Wednesday. As the markets closed, it was up 0.5% on the euro and nearly 0.4% on the pound. Sterling took the middle path, ending the day slightly up on the euro. While there was no major economic news in the UK on Wednesday, the chief executive of pharmaceutical company Eli Lilly, maker of weight loss drug Mounjaro, said the UK is “probably the worst country in Europe” for drug prices.
Coverage Details
Total News Sources7
Leaning Left1Leaning Right3Center1Last UpdatedBias Distribution60% Right
Bias Distribution
- 60% of the sources lean Right
60% Right
L 20%
C 20%
R 60%
Factuality
To view factuality data please Upgrade to Premium